High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer

High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer

Abstract Background To improve the prognosis of patients with metastatic colorectal cancer (mCRC), investigating predictive biomarkers of their prognosis and chemotherapeutic responsiveness is necessary. This study aimed to analyze the clinical significance of serum proteinase-3 (PRTN3) as a predict...

Full description

Bibliographic Details
Main Authors: Kei Furuya, Masao Nakajima, Ryouichi Tsunedomi, Yuki Nakagami, Ming Xu, Hiroto Matsui, Yukio Tokumitsu, Yoshitaro Shindo, Yusaku Watanabe, Shinobu Tomochika, Noriko Maeda, Michihisa Iida, Nobuaki Suzuki, Shigeru Takeda, Shoichi Hazama, Tatsuya Ioka, Yoshinobu Hoshii, Tomio Ueno, Hiroaki Nagano
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Cancer
Subjects:
Biomarker
Bevacizumab
Chemotherapy
Metastatic colorectal cancer
Proteinase-3
Online Access:https://doi.org/10.1186/s12885-024-11924-4

Internet

https://doi.org/10.1186/s12885-024-11924-4

Similar Items